Dr. George Daley, SAB Co-Chair and Scientific Co-Founder
Dr. George Daley is director of Stem Cell Transplantation at the Children's Hospital and Dana Farber Cancer Institute, The Samuel E. Lux IV Chair in Hematology, and professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Daley's lab was among the first to produce human induced pluripotent stem cells and disease-specific stem cells. As a clinician-scientist, Dr. Daley has extensive experience in translating promising science into novel therapeutics.
Dr. Deepak Srivastava, SAB Co-Chair and Scientific Co-Founder
Dr. Deepak Srivastava is the director of the Gladstone Institute of Cardiovascular Disease, a professor of the departments of Pediatrics and Biochemistry and Biophysics, and Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology at the University of San Francisco (UCSF). Dr. Srivastava’s research focuses on understanding the causes of heart disease and on using knowledge of cardiac developmental pathways to devise novel therapeutics for human cardiac disorders.
Dr. Lee Rubin, SAB and Scientific Co-Founder
Dr. Lee Rubin is director of Translational Medicine at the Harvard University Stem Cell Institute. His research has focused on identifying therapeutics for disorders such as SMA, ALS, Huntington's Disease and multiple sclerosis using novel stem cell-based screens and assays.
Dr. Shinya Yamanaka, SAB and Nobel Prize in Medicine 2012
Dr. Shinya Yamanaka received his M.D. from Kobe University in 1987 and his Ph.D. from Osaka City University in 1993. He completed his residency at the National Osaka Hospital, and then served as a postdoctoral fellow at the Gladstone Institute of Cardiovascular Disease where he discovered NAT 1, which was later recognized as an indispensable gene in the differentiation of embryonic stem cells. He returned to Osaka City University Medical School to take an assistant professor position in 1996, and was then appointed as an associate professor at Nara Institute of Science and Technology in 1999, where he became a full professor in 2003. He moved on to his current position as a Professor at Kyoto University in 2004, and received an appointment as a visiting scientist at the Gladstone Institute in 2007. Having successfully established induced pluripotent stem cells, he was appointed as Director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University in 2008. He was awarded the Nobel Prize in Medicine in 2012 for his breakthrough discovery of iPSCs.
Dr. Lennart Mucke, SAB
Dr. Lennart Mucke is the director and senior investigator of the Gladstone Institute of Neurological Disease, and a professor of Neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on Alzheimer’s disease and related neurodegenerative disorders.
Dr. Kevin Eggan, SAB
Dr. Kevin Eggan, is assistant professor in the Department of Stem Cell and Regenerative Biology at Harvard University, principal investigator at the Harvard Stem Cell Institute, and assistant investigator at the Stowers Medical Institute. Dr. Eggan is a world authority on somatic cell reprogramming by nuclear transfer, and the applications of iPS cells to model neurodegenerative disease.
Dr. Bruce Conklin, Scientific Advisor
Dr. Bruce R. Conklin utilizes bioinformatics, receptor engineering, and stem cell biology to understand basic pharmacological responses. He currently serves as senior investigator at the Gladstone Institute of Cardiovascular Disease, and professor of Medical Genetics at the University of California, San Francisco. Dr. Conklin served as the founding director of the Gladstone Genomics Core and the founding director of the Gladstone Stem Cell Core. He was previously associate director of the General Clinical Research Center at San Francisco General Hospital. Dr. Conklin received an A.B. degree in public health from the University of California, Berkeley. He received his M.D. from Case Western Reserve University, completed his internal medicine residency at Johns Hopkins, and his postdoctoral training in molecular pharmacology at UCSF.